A new analysis published in BMJ Global Health underscores the urgent need for healthcare infrastructure investment across Africa to enable delivery of advanced gene therapies for sickle cell disease. With 300 million people carrying the sickle cell trait—predominantly in sub-Saharan regions—the continent faces a treatment accessibility crisis. Current hematopoietic stem cell transplantation programs reach fewer than 1% of eligible patients, leaving millions without access to transformative care options.
Emerging gene editing technologies like CRISPR-Cas9 demand specialized facilities including ultra-low temperature storage, clean rooms, and rigorous quality control systems that exceed current capacity in most African healthcare settings. The research emphasizes that successful implementation requires coordinated investment in cold chain logistics, laboratory accreditation, and specialized workforce training.
While South Africa, Nigeria, and Kenya demonstrate advanced preparedness with established transplantation centers, rural populations across all nations remain underserved. Strategic infrastructure development could fundamentally transform treatment access within the next decade.
Read the full article on GMJ Newsroom.
Was this article helpful?
